The growth of Viagra and its influence on the medicinal landscape presents a complicated question for shareholders. While the early sales statistics were impressive, the intellectual property has lapsed, leading to a flood of off-brand alternatives that are chipping away at revenue. Moreover, the market is facing issues related to demographic trend